Analysis Short Term Effect Of Clinical And Pathologic Factors Related To Recombinant Human Endostatin Combined With Chemotherapy For Advanced Non Small Cell Lung Cancer

Objective: The retrospective study of curative effect of Receombinant humanendostatin (Endostar, YH-16) combined with chemotherapy for advanced non small celllung cancer.The study is designed to get a comprehensive observation of the responserate, the disease control rates, and safety of combined with chemotherapy for advancednon small cell lung cancer(NSCLC).Materials and Methods:1. Using the retrospective study of clinical and following the Inclusion criteria. Atotal of75patients with advanced non small cell lung cancer were selected from theDalian Medical University of Oncology of the First Affiliated Hospital of DalianMedical University from2009to2012.2. According to treatment protocols, all patients treated with Endostar combinedwith chemotherapy. Histological type according to the WHO histological classification(1998). Staging of lung cancer in accordance with the provisions of the1997International Union Against Cancer (UICC) TNM classification. We used mixture withEndostar7.5mg/m2and NS500ml, about15mg per day,>4h, ivgtt on days1to14, and21-d cycle. We would get evaluate of curative effect after2cycles. And evaluate oftoxicity complications will get after1cycle.3. Compared between groups use chi-square test, Level data Wilcoxon test was used, allof them use two-sided test, them will reach statistical significance when the P value lessthan0.05. All of those methods from the software package of statistics (SPSS19.0).Result:1. The short term effect of YH-16combined chemotherapy related to clinical featuresand chemotherapeutic1.1In the group of age≤60and>60, age the DCR was92.2%and75.0%, respectively (p=0.041), with statistic significant, DCR in the group of≤60was higher; RR was23.5%and28.0%（p=0.795）, without statistic significant.1.2DCR, RR have no related to sex, ECOG score, have or not smoking,there was nosignificant difference（P＞0.05）.2. The short term effect of YH-16combined chemotherapy related to Clinical stage2.1NSCLC Phase III and IV patients with DCR respectively for75.9%and89.1%(p=0.127), DCR and clinical stage have no significant difference; NSCLC Phase III and IVpatients with RR were10.3%,32.6%(p=0.028), RR and clinical staging related, havea significant difference of IV RR compared to the Phase III was hegher;2.2The short term effect of YH-16combined chemotherapy related to the transferorgans number with stage IVIV NSCLC patients46cases,≤2organ transfer,>2metastases DCR respectivelyfor the96.3%,79.0%(p=0.063), the DCR and IV of transfer of organs have nocorrelation, no significant difference.≤2metastases> the two metastases RR was44.4%,15.8%(p=0.041), RR and IV of the number of transfer of organs havestatistically significant,≤2the organ metastasis RR compared with> two metastases washigher.3. The short term effect of YH-16combined chemotherapy related to Pathologicalfeatures3.1The short term effect of YH-16combined chemotherapy related to Pathologicaltype.Adenocarcinoma and squamous cell carcinoma of the DCR for92.0%,68.0%(p=0.008), DCR related to pathological type, with statistically significant differences, DCRin adenocarcinoma was higher than squamous cell carcinoma; adenocarcinoma andsquamous cell carcinoma of the RRwere20.0%,32.0%(p=0.251), the RR andpathologic type, have no significant difference.3.2The short term effect of YH-16combined chemotherapy related to Adenocarcinomadifferentiation50adenocarcinomas suffering from high, medium, poorly differentiated DCR were91.7%,87.5%,95.5%(p=0.671), DCR with adenocarcinoma of no correlation betweenthe degree of differentiation, without significant difference; RR was respectively, for8.3%,6.4%,36.4%(p=0.037), the RR and adenocarcinoma degree of differentiation, have statistically significant, poorly differentiated RR was higher than moderately.andhigh differentiated.4. The short term effect of YH-16combined chemotherapy related to serum CEAPre-treatment levelPre-treatment elevated serum CEA normal DCR were92.5%,74.3%(p=0.032),the DCR with pre-treatment serum CEA level, a significant difference, elevatedpre-treatment serum CEA DCR compared with CEA normal; elevated pre-treatmentserum CEA normal RR respectively for35.0%and11.4%(p=0.017), RR andpre-treatment serum CEA level correlation, statistically significant elevatedpre-treatment serum CEA by RR higher than normal.5. The short term effect of YH-16combined chemotherapy related to treatmentDCR, RR and past therapy, combination chemotherapy was no correlation, nosignificant difference (P>0.05)Conclusion:1. YH-16combined with chemotherapy, RR was related with age, less than60-year-oldRR greater the age of60have the advantage.2. YH-16combined with chemotherapy, RR was related with clinical staging, stage IVRR was higher than the Phase III. IV NSCLC patients, the RR was related with transferthe number of organs, less than two metastases RR2metastases advantage.3. YH-16combined with chemotherapy, DCR was related with pathological types,adenocarcinoma than squamous cell carcinoma RR advantage. In patients withadenocarcinoma, RR was related with adenocarcinoma of the degree of differentiation,poorly differentiated RR was higher than differentiated advantage.4. YH-16combined with chemotherapy, DCR, RR was related with pretreatment serumCEA level, the treatment of former CEA increased DCR, RR were higher than thenormal.5. YH-16combined with chemotherapy, DCR, RR were not correlated to gender,ECOG score, smoking status, previous treatment, the joint chemotherapy.